Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ip Group Plc LSE:IPO London Ordinary Share GB00B128J450 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.80 0.7% 114.40 114.40 114.80 114.80 112.00 112.00 1,579,248 16:35:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.0 186.1 17.5 6.5 1,215

Ip Share Discussion Threads

Showing 2326 to 2347 of 2550 messages
Chat Pages: 102  101  100  99  98  97  96  95  94  93  92  91  Older
DateSubjectAuthorDiscuss
04/5/2021
07:48
Mas, thanks. Over 4 months approx 6% added to the ONT valuation.
bamboo2
04/5/2021
07:21
IP Group Portfolio company Oxford Nanopore Technologies raises £195m in new investment IP Group plc, notes that portfolio company Oxford Nanopore Technologies Ltd has raised £195m in new capital including £125m from new investors Temasek, Wellington Management, M&G Investments and Nikon with existing shareholders investing £70m. IP Group committed £18.7m to the round, being its full pre-emptive allocation. Following completion of the round, IP Group has a 14.5% undiluted beneficial stake in Oxford Nanopore, valued at £359m.
masurenguy
02/5/2021
14:31
Gap 6/4/2021 remains unfilled, it measures 126.4-126.6 My chart showing a possible turn 4/5/2021, which I guess if it materialises, will be a low turn. Once it's filled, price should be able to move on.
bamboo2
01/5/2021
17:16
Also mentioned in this article. https://www.standard.co.uk/business/pharmaceuticals/arix-acacia-neil-woodford-biotech-investment-b932706.html
eeza
01/5/2021
17:06
Oxford Nanopore will comprise nearly half of Neil Woodford's new offering from WCM Partners, according to a document sent to potential investors. The WCM Partners Healthcare Portfolio will be composed of eight UK and US healthcare technology businesses, all of which were previously held by Woodford across his old funds. Oxford Nanopore Technologies will comprise almost half of the entire fund, with a 43% weighting, with Viamet and Immunocore the second and third largest holdings at 18% and 12% respectively. According to an email sent as part of an unsolicited approach, the portfolio has "significant pre-interest" and currently stands at £330m. While WCM Partners is registered in the UK, WCM Partners Healthcare, the company name featured on the proposition, is based in the Cayman Islands rather than the originally touted Jersey. hxxps://www.investmentweek.co.uk/news/4030481/oxford-nanopore-represents-half-cayman-woodford-fund
bamboo2
29/4/2021
08:55
do many know much about hinge health? this unicorn has popped up from relatively nowhere. my understanding is there are over 100 holdings in ip stable . i guess there will be say another 2 or 3 unicorns hiding in there too?
edwardt
26/4/2021
09:26
Pierre, in terms of current NAV, allowing for the last quarters uplift in ONT this is probably fairly valued at 134. Obviously there will be a premium added on to the ONT valuation, but this is currently unknown. There are probably also other constituents with improved valuations since end of 2020. My guess is that there are some holders who have bought on the way up taking profits, although the chart does suggest that the stock is still being accumulated. Good to see you become more positive!
bamboo2
26/4/2021
08:51
A little confused at the lack of response to the nano news.Nano is a very big deal for IPO and nowhere near reflected in IPOs price yet. Easy to see this climbing purely on the back of nano as it's float gets nearer.
pierre oreilly
25/4/2021
21:03
Thanks Mas. UK govt is a major ONT customer and the UK Govt need to promote the City as open for business. Hence the London listing.
bamboo2
25/4/2021
13:44
rob, Can you paste the text here?
bamboo2
25/4/2021
12:56
Big positive article on ONT in the Sunday Times business section today. Think it is the start of the IPO pr campaign
robertspc1
21/4/2021
08:09
Gap 6/4/2021 remains unfilled for now. Measures 126.4-126.6
bamboo2
21/4/2021
07:36
wba, I agree, there are many aspects of the Website that need updating. Write a quick email about it to IPGroup Investor Relations. They are very good at replying.
bamboo2
20/4/2021
16:28
Not a big issue, but I was surprised to find that the Portfolio News section on the website is less than comprehensive. I would have thought recent news on funding and device approval for Alimetry would be more newsworthy than (say) news of a director change at Actual Experience - but you only find it by going to the Australia site, and even then Alimetry is not listed on the portfolio but only comes up on the news. It would be useful if they pulled together news from all across the group.
wba1
19/4/2021
22:41
I see nano got a bit of the £3bn the government is throwing at pharma atm. Shared between about 100 pharmas means about £30m each on average, spread over about 3 years. The point is, gov spending on pharma is going to increase after decades of underinvestment - and the floundering around in the current pandemic, together with the trillions costs to economies as devastation to almost everyone's quality of life, ensures we'll be better prepared next time. Pharmas, which ip has stakes in many, are like shooting fish in a barrel atm.
pierre oreilly
16/4/2021
10:45
Indeed. I think Oxbotica is a unicorn in the making.
robertspc1
16/4/2021
09:59
It will be interesting to see what value IP puts on Oxbotica at the next report. At the end of 2020 it was valued at £15m for the 16.4% stake, valuing the company at £91m or 105m euro. Dealroom gave an estimated value of 171-256m euro after the January series B round, and one assumes a link with Ocado will not have harmed that figure. So it seems that there is room for a material uplift in carry value.
wba1
16/4/2021
09:11
16.4% as of 31st Dec 2020. This is from IP Group's own website
benchmark
16/4/2021
08:58
Ocado tie up with Oxbotica today. How much of Oxbotica does IPO own ??
robertspc1
12/4/2021
10:47
I got a second tranch today, paid a bit more than i wanted but never mind. Ipo has been undervalued due to invesco forced selling, but now more or less recovered from that. Main reason is the board is being more progressibve, and it has lots of undervalued assets due to the recovery, especially in speculative pharma stocks. It only needs one or two of the tiny pharma punts to come off and give how many they hold it look reasonable. Short/medium term weve got the nano float, which will get this noticed. Longer term we have an explosion in pharma spending. As holding get revalued, ths will sit on a discount again, and it's reasonable that it trades at a premium. I don't like the big costs it takes every year, but looking at how many are sitting around inventing those complex valuing criteria and applying them (for very little benefit i can see), then they always will take big charges. With an eye on regulatory requirements, they could simply assign a fair value of 95% for ftses, 90% of 250s, 70% for aim, 50% for their next risk class and zero for their illiquid class. Job done, just as good as their hypercomplex valuation method but at pretty much zero cost. 25% saving in their 21m cost base there.
pierre oreilly
12/4/2021
09:29
Thanks chaps. I had read the report but had some difficulty aligning a £42m carry value with a calculation of £52m based on a finance transaction contemporaneous with the valuation and which would itself be set/adjusted (call it what seems best) to reflect some discount to market value (unless it was pretty unusual). However I am more than content if IP habitually take that conservative a view of fair value as it implies significant hidden value within the portfolio (in addition to recent developments on the likes of Oxford and Artios). Before this discussion I had thought, looking through the portfolio, that IP had taken a very conservative view on Oxford and Artios given competitor values and news known at year end such as Merck. But I did think Hinge looked high even at £42m. Whilst Oxford and Artios seem to have real intellectual assets underpinning their proposition, Hinge (to me) looks far more of a fairly replicable fashion (in the business sense) outfit. Hope I am wrong, but if not the others more than outweigh it.
wba1
11/4/2021
20:35
wba, this is the info on valuations from the last results. Hinge Health latest round [6/1/2021] was post period, therefore not included in the latest results. =============================== Fair value hierarchy The Group classifies financial assets using a fair value hierarchy that reflects the significance of the inputs used in making the related fair value measurements. The level in the fair value hierarchy, within which a financial asset is classified, is determined on the basis of the lowest level input that is significant to that asset's fair value measurement. The fair value hierarchy has the following levels: Level 1 - Quoted prices in active markets. Level 2 - Inputs other than quoted prices that are observable, such as prices from market transactions. Level 3 - One or more inputs that are not based on observable market data. Equity investments Fair value is the underlying principle and is defined as "the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date" (IPEV guidelines, December 2018). Where the equity structure of a portfolio company involves different class rights in a sale or liquidity event, the Group takes these different rights into account when forming a view on the value of its investment. Valuation techniques used The fair value of unlisted securities is established using appropriate valuation techniques in line with IPEV guidelines and including IPEV's special guidance issued in March 2020 in response to Covid-19. The selection of appropriate valuation techniques is considered on an individual basis in light of the nature, facts and circumstances of the investment and in the expected view of market participants. The Group selects valuation techniques which make maximum use of market-based inputs. Techniques are applied consistently from period to period, except where a change would result in better estimates of fair value. Multiple valuation techniques may be used so that the results of one technique may be used as a cross check/corroboration of an alternative technique. Valuation techniques used include: -- Quoted investments: the fair values of quoted investments are based on bid prices in an active market at the reporting date. -- Milestone approach: an assessment is made as to whether there is an indication of change in fair value based on a consideration of the relevant milestones typically agreed at the time of making the investment decision. -- Scenario analysis: a forward-looking method that considers one or more possible future scenarios. These methods include simplified scenario analysis and relative value scenario analysis, which tie to the fully diluted ("post-money") equity value, as well as full scenario analysis vie the use of the probability-weighted expected return method (PWERM). -- Current value method: the estimation and allocation of the equity value to the various equity interests in a business as though the business were to be sold on the Measurement Date. -- Discounted cash flows: deriving the value of a business by calculating the present value of expected future cash flows. -- Multiples: the application of an appropriate multiple to a performance measure (such as earnings or revenue) of the Investee Company in order to derive a value for the business. The fair value indicated by a recent transaction is used to calibrate inputs used with valuation techniques including those noted above. At each measurement date, an assessment is made as to whether changes or events subsequent to the relevant transaction would imply a change in the investment's fair value. The Price of a Recent Investment is not considered a standalone valuation technique (see further considerations below). Where the current fair value of an investment is unchanged from the price of a recent financing, the group refers to the valuation basis as 'Recent Financing'. Price of recent investment as an input in assessing fair value The Group considers that fair value estimates which are based primarily on observable market data will be of greater reliability than those based on assumptions. Given the nature of the Group's investments in seed, start-up and early-stage companies, where there are often no current and no short-term future earnings or positive cash flows, it can be difficult to gauge the probability and financial impact of the success or failure of development or research activities and to make reliable cash flow forecasts. Consequently, in many cases the most appropriate approach to fair value is a valuation technique which is based on market data such as the price of a recent investment, and market participant assumptions as to potential outcomes. Calibrating such scenarios or milestones may result in a fair value equal to price of recent investment for a limited period of time. Often qualitative milestones provide a directional indication of the movement of fair value. In applying a calibrated scenario or milestone approach to determine fair value consideration is given to performance against milestones that were set at the time of the original investment decision, as well as taking into consideration the key market drivers of the investee company and the overall economic environment. Factors that the Group considers include, inter alia, technical measures such as product development phases and patent approvals, financial measures such as cash burn rate and profitability expectations, and market and sales measures such as testing phases, product launches and market introduction. Where the Group considers that there is an indication that the fair value has changed, an estimation is made of the required amount of any adjustment from the last price of recent investment. Where a deterioration in value has occurred, the Group reduces the carrying value of the investment to reflect the estimated decrease. If there is evidence of value creation the Group may consider increasing the carrying value of the investment; however, in the absence of additional financing rounds or profit generation it can be difficult to determine the value that a market participant may place on positive developments given the potential outcome and the costs and risks to achieving that outcome and accordingly caution is applied.
bamboo2
Chat Pages: 102  101  100  99  98  97  96  95  94  93  92  91  Older
ADVFN Advertorial
Your Recent History
LSE
IPO
Ip
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210622 04:14:32